Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $38.50 Average Price Target from Brokerages

by · The Cerbat Gem

Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) has earned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $38.50.

A number of analysts recently weighed in on ALGS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a report on Friday, May 29th. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Lake Street Capital began coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Weiss Ratings downgraded Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th.

Check Out Our Latest Research Report on Aligos Therapeutics

Aligos Therapeutics Stock Down 2.1%

ALGS stock opened at $5.56 on Thursday. The firm has a market capitalization of $34.72 million, a PE ratio of -0.76 and a beta of 2.34. Aligos Therapeutics has a twelve month low of $3.98 and a twelve month high of $13.69. The stock has a 50-day simple moving average of $5.76 and a two-hundred day simple moving average of $6.15.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.95. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. The firm had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million. On average, equities research analysts anticipate that Aligos Therapeutics will post -6.81 EPS for the current fiscal year.

Institutional Trading of Aligos Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Aligos Therapeutics by 1,652.8% during the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after purchasing an additional 216,646 shares in the last quarter. SummitTX Capital L.P. raised its stake in Aligos Therapeutics by 6.7% in the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after purchasing an additional 9,375 shares in the last quarter. Renaissance Technologies LLC raised its stake in Aligos Therapeutics by 17.6% in the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after purchasing an additional 15,006 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its position in Aligos Therapeutics by 900.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares during the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

(Get Free Report)

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases, viral infections and related conditions. The company uses its research platforms to discover and advance small-molecule therapies designed to address significant unmet medical needs.

Its development programs have included treatments for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH) and viral respiratory diseases. The company’s hepatitis B pipeline has included capsid assembly modulators, while its MASH efforts have included therapies intended to improve liver health and reduce disease progression.

Featured Stories